Objectives: To review health economic models of population screening for abdominal aortic aneurysm (AAA) among elderly males and assess their credibility for informing decision-making.
Introduction
In the UK, decision analytic models are increasingly used to estimate the costs and outcomes of alternative health care interventions. Cost-effectiveness data presented to the National Institute for Health and Clinical Excellence (NICE), the body responsible for appraising health technologies on behalf of the UK National Health Service (NHS), are largely model based. 1 The appeal of decision modelling is its versatility. Its uses include extrapolation beyond trial outcomes, evidence synthesis, generalization of study results to alternative settings and identification of future research priorities. 2 However, concerns about decision models (notably a lack of methodological rigour and transparency) have been raised and policy-makers still regard decision model findings with caution.
Population ultrasound screening for abdominal aortic aneurysm (AAA) in elderly males provides a good example. The effectiveness and cost-effectiveness of a national screening programme for AAA has been debated in many countries over many years. 3, 4 First attempts around 1990 to determine the likely costeffectiveness of a screening policy involved some simple modelling studies. 5, 6 By 2000, the number of models had increased substantially. A large pragmatic randomized trial of AAA screening in the UK provided the first trial-based estimates of effectiveness and resourceuse in 2002. 7 But with follow-up limited to four years, analysts have continued to develop models to estimate long-term cost-effectiveness. However, there is little evidence that these models have assisted decisionmakers in determining whether or not screening for AAA is cost-effective. As of October 2005, longstanding decisions to refrain from screening all elderly males, which were made in the absence of definitive costeffectiveness evidence, continue to be upheld in the United States, 3 Canada, 4 
and the UK.
That policy-makers appear unable or unwilling to make recommendations for (or against) AAA population screening on the basis of results generated predominantly by decision analytic models, raises a number of important questions. The aim of this paper was to identify and review published AAA screening models, with a view of determining their credibility for informing policy.
AAAs and screening
AAAs are present in 5-7% of men over 65 and account for approximately 2% of deaths in this group in the UK. In most cases, the aortic dilation is asymptomatic, going undetected until rupture. Prognosis following rupture is bleak as around half of patients will die before they reach hospital and the remaining half will face emergency surgery mortality rates ranging from 30% to 70%. Ultrasound is a low-cost, non-invasive, sensitive and specific screening test for early detection of AAA. Following detection, AAAs can be monitored for growth, and patients referred for elective surgical repair when the aneurysm exceeds a size beyond which the probability of rupture is considered high.
Methods
Full details of the terms used and databases included in the search for health economic models of AAA screening are available as a web appendix together with other methodological details. The web appendix may be viewed free of charge at http://www.ingentaconnect.com/ content/rsm/jhsrp/2007/00000012/00000001/art00005. All fields within databases were searched in February 2005 for papers or reports published up to and including 2004, with no language restrictions. Papers reporting health economic models were reviewed, and costs expressed as 2003/2004 £ Sterling to facilitate a comparison of results.
Only models for population screening among elderly males were critically appraised. The structure of each model was assessed using guidelines for good practice in decision analytic modelling in health technology assessment (Table 1) . 8 An appraisal of the data used to inform three key parameters (a clinical parameter, a cost parameter and an outcome parameter) common to each model was also carried out. For each, an assessment was made of the methods used to (1) identify, (2) incorporate and (3) handle uncertainty around model input data. 9 Where papers had referenced another publication as the source of input data, this publication was retrieved and reviewed.
Results
Twelve health economic models of AAA screening were identified. Table 2 presents base-case results reported or derivable for each model. Where studies reported results for more than one screening strategy, or for different patient groups, those pertaining to a single ultrasound screen, and to all elderly males, were sought. Where estimates of the additional cost per patient resulting from AAA screening were reported, values ranged from £65 to £460. Effect differences ranged from -0.001 to 0.28 among studies reporting life years and 0.031 to 0.077 among those reporting quality-adjusted life years (QALYs). Incremental cost per life year gained figures ranged from À£101,443 to £35,187, and incremental cost per QALY figures from £817 to £7,738.
A detailed assessment of the structure and input parameter values of nine of the models in Table 2 was undertaken. The remaining three models were excluded (grey shading in Table 2 ), two because their focus was targeted ultrasound screening for familial AAA, 10, 11 and one because analysts failed to report any of the statistics in Table 2 
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Model structures
All papers had a stated objective to estimate the costeffectiveness of a population ultrasound screening programme for AAA compared with no screening. Only two papers provided details of funding sources, and none indicated whether the modelling had been commissioned directly by a health care provider or conducted independently. The study viewpoint was explicitly stated in only one paper, 13 although all models used inputs consistent with a health care provider's perspective. Consideration of the strategies being modelled showed the age at which men were initially screened varied from 60 to 79. In six papers, [13] [14] [15] [16] [17] [18] a policy of a single (or prevalence) population screen was modelled and in three papers, policies involving multiple population screens were presented. 5, 6, 19 If estimates of the annual incidence of new AAA of 0.1% per annum are to be believed, 15, 19 then the prevalence of AAA at subsequent screens will be small. In terms of costeffectiveness, and when comparing against a policy of no screening, one might expect a policy involving re-screens of the same cohort to appear less favourable than a single screen strategy. Table 2 , however, shows that incremental cost-effectiveness ratios (ICERs) from two of the three studies were among the three most favourable reported. 5, 6 Cross-referencing model type with the results in Table 2 revealed that the three studies reporting the lowest ICERs 5,6,18 were also the three not employing a decision analytic framework to model explicitly costs and effects. Although a number of terms (including mathematical model, computer spreadsheet model and Markov model) were used to describe the remaining six models, each used Markov modelling. The underlying disease process appears to provide the rationale for the structure of these six models, with the health states included in each model reflecting important clinical stages in the disease process (e.g. no AAA, small, medium and large AAA). Each model appears to cycle on a yearly basis; however, in only one paper, 17 this is stated explicitly.
In terms of the time horizon modelled, five studies conducted a lifetime analysis, 5,14,16-18 three used 20 years, 6, 15, 19 and one used 15 years. 13 Given the starting age of the patient cohort, 15 or 20 years might be considered broadly equivalent to a lifetime analysis and therefore time horizon is unlikely to be a significant factor contributing to disparate results.
Eight of the nine models incorporated two or more simplifying structural assumptions favouring screening, and so cost-effectiveness results could be overly optimistic. Four of the nine models appear to assume that without screening, opportunistic detection of AAA and resultant elective repairs would not occur. 5, 6, 13, 14 Although data on AAA diagnosis in the absence of screening are scarce, patients still undergo elective AAA repair in the absence of formal screening programmes. Omitting some level of natural case finding will over-estimate to some degree lives saved and life years gained by implementation of such screening. In a oneway sensitivity analysis conducted by one of the five models, which allowed for opportunistic detection, reduction of the base-case estimate from 6.6% per year to zero had only a small effect on the ICER. 16 Four of the nine models seem to be structured for 100% attendance at screening. 6, 15, 16, 19 Pilot studies of AAA screening have suggested attendance of around 80%. An assumption that all invited patients attend will tend to make screening appear more favourable than it would be in routine practice. Ideally models should reflect the positive association between attendance rates and invitation costs (i.e. only re-invitation and persistent follow-up of non-responders can improve turnout). Table 2 shows that despite assuming 100% take-up of screening, three of these four studies still generated the highest ICERs. One-way sensitivity analysis by one of the models structured for non-attendance suggested only small reductions in cost-effectiveness as attendance declines. 17 All nine analyses assume ultrasound sensitivity and specificity to be 100%. While the test is unlikely to be perfectly accurate, evidence suggests its sensitivity and specificity are close to 100%. 20 Given the uniformity of this assumption, it cannot be a factor contributing to the between-model differences in cost-effectiveness results.
Assumptions about the impact of screening upon AAA rupture vary between studies. Table 3 shows that one study assumes that screening will completely eliminate rupture and emergency surgery. 19 In addition to 100% attendance at screening and 100% sensitivity and specificity of ultrasound, two further assumptions would need to hold in order for this to be true: firstly no ruptures in patients with screendetected AAA below the threshold for surgery, and secondly all patients with screen-detected AAA exceeding this threshold undergo elective repair without delay. As the threshold for surgery used in this study is small (40 mm) and rupture of an AAA of this size is unlikely, the first of these two assumptions could be considered valid. That all patients indicated for elective repair will undergo the procedure is, however, improbable, although Table 3 shows a further two studies also making this assumption. 6, 16 Only five of the papers acknowledged that not all patients exceeding the threshold for elective repair would undergo surgery, either because they refused or were contraindicated for the procedure, or because they failed to attend the initial screen and their AAA remained undetected. 5, [13] [14] [15] 17 Table 3 suggests that the size of aneurysm threshold beyond which elective repair is indicated has increased over time. The four most recent studies, which use larger diameter thresholds, all acknowledge a small risk of rupture below this size. It is difficult to determine the impact of these assumptions upon cost-effectiveness results. From Table 3 , it could be inferred that two models 13, 17 simulate the most likely impact of screening
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Elective AAA repair mortality rate
Base-case estimates of this parameter varied between studies. (Table 2 on web) The two studies using the lowest rates 5, 18 produced the lowest cost-effectiveness ratios. Higher mortality rates, however, were not always associated with less favourable results. Only two studies provided details of bibliographic searches to identify papers to inform this parameter value. 15, 17 Three studies provided no reference at all for the base-case estimate used. 5, 16, 18 Of the six studies that did cite sources, three referenced just one publication [13] [14] [15] (although one of these contained results of a Medline review), and one each referenced two papers, 17 three papers, 6 and four papers. 19 Of those studies citing more than one source, none provided information on how estimates from these studies were synthesized to generate the base-case value incorporated within the model. Four of the nine studies reported sensitivity analyses for this parameter. Of the three performing one-way analyses, two demonstrated that small changes in mortality following elective AAA repair would have a large impact upon cost-effectiveness. 14, 19 The reporting of sensitivity analysis results from the third study, however, did not use the ICER. 13 The remaining paper carrying out sensitivity analysis for this parameter did so as part of a multivariate analysis. 15 
Cost of emergency AAA repair
The assumed cost of emergency AAA repair varied substantially across the nine models. (Table 3 
on web)
Around half of the analysts used a base-case cost that they had estimated themselves [16] [17] [18] [19] and in one paper both a locally calculated cost and a published cost were used. 13 For just two of these studies, detail was available (in a further published paper) on resource-use included in the estimate, and costing methods used. 13, 16 Of the remaining four studies, cost estimates used by three appear to be based on expert clinical opinion 5, 6 or personal communication 14 and one study referenced a single paper reporting a costing exercise. 15 Details on the costing methods employed and resource-use included in this estimate were not, however, reported.
Four of the nine studies reported sensitivity analyses for the cost estimate of emergency AAA repair. Two of these studies undertook one-way sensitivity analyses; 13, 19 however, it was possible to determine the impact of variation in the cost estimate on the ICER for only Bengtsson et al. 19 who found that doubling the emergency surgery cost reduced their base-case incremental cost per life year by 30%. Of the remaining two studies, one reduced the costs of elective and emergency repair to the same value simultaneously, 14 while the impact of varying the cost of emergency AAA repair in the remaining paper was again assessed at the same time as other parameter values were varied. 15 
Utility levels assigned to life years modelled
Of the four studies using the QALY as their outcome measure, two assigned a utility level of one to all life years modelled. 13, 18 (Table 4 on web) Neither of these studies provide justification for such an assumption, nor do they examine uncertainty surrounding this value. Perfect health was also generally assumed for patients in another model; however, utility for AAA repair survivors in this model was reduced slightly in the three-month period following surgery to reflect 17 Yes 50 mm Yes Ã Text accompanying model acknowledges that not all patients identified as surgery candidates will undergo elective AAA repair. Whether ruptures occurring in this group are fed through into the modelling is unclear w It is acknowledged that rupture and emergency surgery will still occur with screening, but the AAA size at which rupture is permitted is not specified z 40 mm mentioned in text as a likely threshold for surgery, inclusion in the model is unclear y Text accompanying model acknowledges that rupture will still occur below the threshold for surgery. Whether this is fed through into the modelling is unclear NA -information not available procedure-related morbidity. 5 Disutility associated with AAA repair was also incorporated within the model by Lee et al., 16 as were utility levels associated with possible long-term complications. Again no sources were provided for utility values used and no sensitivity analyses exploring the impact of alternative values were conducted.
Discussion
There is a lack of agreement between models, which raises questions about the overall quality of the modelling employed. Any decision-maker attempting to review these models would be confronted with poor reporting of results. In only four papers, it was possible to derive estimates of the mean per patient costs and outcomes with and without screening. No improvement in the standard of reporting over time was apparent.
Although 10 models generated ICERs well below £20,000 (which is likely to be considered cost-effective in most jurisdictions), 21 considerable uncertainty surrounds the additional costs that would need to be incurred to generate additional health benefit. Given the substantial number of factors with the potential to influence model results, attributing these differences to specific modelling techniques, structural assumptions or parameter values is simply not possible. We can only speculate about the possible relative impact of different study components. Model type, for example, could be a contributing factor -none of the three studies generating results most favourable to screening constructed a model framework to model costs and effects explicitly.
Examination of structural or simplifying assumptions revealed eight of the nine population screening models to have incorporated at least two assumptions, which would artificially favour a screening programme. Although consideration of each assumption in isolation suggested the likely impact in terms of overestimating cost-effectiveness might be small, the collective impact of these assumptions on the results of each model is uncertain, and effectively impossible for a decision-maker to determine. It might be concluded that Law et al. 6 incorporated the most number of assumptions in favour of screening and that this resulted in a model generating one of the lowest ICER values. In contrast, the model by Boll et al. 17 incorporated the least number of structural assumptions in favour of screening. However, it too generated results highly favourable towards screening.
One other possible source contributing to the divergent results are the data used to populate these models. Having to compare and ascertain the quality of all input parameter values across all nine models highlights the enormity of the task facing the decision-maker. Assessing data quality for just three model parameters revealed a wide range of input values for each. The relation with reported results was not always intuitive, given the base-case parameter values reported.
Disparate results among models evaluating the same interventions have been observed elsewhere. [22] [23] [24] When convergent validity between models is low, and reconciliation of disparate results not achievable, the decision-maker will need to determine whether results from any of the models are robust enough to inform policy. For AAA screening models, determining the reliability of model input parameters and consequently of cost-effectiveness results is simply not possible. Good practice guidelines for decision analytic models suggest that the analyst should document all the information sources that have been searched. 9 Such details are rarely reported. Without this information, the decisionmaker cannot judge whether parameter values are appropriate. A lack of methodological rigour in reporting search strategies for identifying data to populate decision models has also recently been observed by Cooper et al. 2 in decision models developed for UK Health Technology Assessments. They found that for model parameters (with the exception of clinical effectiveness data), methods used to identify sources of evidence were rarely reported and appeared to be ad hoc.
In the absence of suitably robust decision models, interaction between researchers and decision-makers could provide an opportunity to improve both the transparency and usefulness of published analyses. In the UK, for example, NICE commissions work and interacts with analysts, which facilitates the modelling of alternative scenarios.
Despite not being able to determine whether models were commissioned directly by decision-makers or conducted by independent analysts, we assumed that models were devised so as to meet the requirements of a decision-maker and would have been known about and considered at the time of policy review. Input parameters were certainly consistent with a health service viewpoint, suggesting the first of these assumptions to be plausible. Furthermore, a recently published synthesis showed that decision-makers systematically search for and identify the majority of published models. 3 
Conclusion
There are a number of reasons why cost-effectiveness models may not have provided an adequate basis to encourage policy-makers to adopt population screening for AAA. First, convergent validity between models is low. Second, it is extremely difficult based upon the data reported in published studies to attribute differences in results to one or more particular sources. Third, poor reporting of methodology makes it difficult to ascertain whether the modelling carried out is of a sufficiently high standard to inform policymaking. There need to be major improvements in the construction and reporting of health economic decision
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Web appendix

Methods
Literature review methods
To identify papers reporting the results of models constructed to estimate the cost-effectiveness of AAA screening, the following search terms were used: Figure 1 shows the flow of publications. Papers identified as reporting health economic models were reviewed and results documented. To facilitate a comparison of results, all costs were inflated to 2003/2004 UK £ Sterling. For non-UK studies identified, costs were inflated to 2003/04 prices using country-specific inflation indices 1 before being converted to UK £ Sterling using published Purchasing Power Parities (PPPs). 2 Ideally, PPPs specific to AAA screening and treatment would have been used -such technology-specific indices are known to accurately account for issues of resource-use mix and price variation, 3 but these were not available. However, given that only western countries feature in the review, it is likely that the potential for resource-use mix to differ substantially in the provision of AAA screening and treatment is small. 
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